<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Drug Des Devel Ther</journal-id>
      <journal-id journal-id-type="iso-abbrev">Drug Des Devel Ther</journal-id>
      <journal-title-group>
        <journal-title>Drug Design, Development and Therapy</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1177-8881</issn>
      <publisher>
        <publisher-name>Dove Medical Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23950639</article-id>
      <article-id pub-id-type="pmc">3741076</article-id>
      <article-id pub-id-type="doi">10.2147/DDDT.S42138</article-id>
      <article-id pub-id-type="publisher-id">dddt-7-723</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mahe</surname>
            <given-names>Julien</given-names>
          </name>
          <xref ref-type="aff" rid="af1-dddt-7-723">1</xref>
          <xref ref-type="corresp" rid="c1-dddt-7-723"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meurette</surname>
            <given-names>Aur&#xE9;lie</given-names>
          </name>
          <xref ref-type="aff" rid="af2-dddt-7-723">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moreau</surname>
            <given-names>Anne</given-names>
          </name>
          <xref ref-type="aff" rid="af3-dddt-7-723">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vercel</surname>
            <given-names>Caroline</given-names>
          </name>
          <xref ref-type="aff" rid="af2-dddt-7-723">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jolliet</surname>
            <given-names>Pascale</given-names>
          </name>
          <xref ref-type="aff" rid="af1-dddt-7-723">1</xref>
          <xref ref-type="aff" rid="af4-dddt-7-723">4</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-dddt-7-723"><label>1</label>Clinical Pharmacology Department, Institute of Biology, University Hospital, Nantes, France</aff>
      <aff id="af2-dddt-7-723"><label>2</label>Clinical Nephrology and Immunology Department, University Hospital, Nantes, France</aff>
      <aff id="af3-dddt-7-723"><label>3</label>Laboratory of Pathology, University Hospital, Nantes, France</aff>
      <aff id="af4-dddt-7-723"><label>4</label>EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Sciences, University of Nantes, Nantes, France</aff>
      <author-notes>
        <corresp id="c1-dddt-7-723">Correspondence: Julien Mahe, Centre R&#xE9;gional de Pharmacovigilance, Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, 9 Quai Moncousu, 44093 Nantes Cedex, France, Tel +33 2 40 08 40 96, Fax +33 2 40 08 40 97, Email <email>julien.mahe@chu-nantes.fr</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>07</day>
        <month>8</month>
        <year>2013</year>
      </pub-date>
      <volume>7</volume>
      <fpage>723</fpage>
      <lpage>728</lpage>
      <permissions>
        <copyright-statement>&#xA9; 2013 Mahe et al, publisher and licensee Dove Medical Press Ltd</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license>
          <license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Interferon beta-1a is available as an immunomodulating agent for relapsing forms of multiple sclerosis. Common side effects include flu-like symptoms, asthenia, anorexia, and administration site reaction. Kidney disorders are rarely reported. In this study we describe the case of a woman who has been undergoing treatment with interferon beta-1a for multiple sclerosis for 5 years. She developed a hemolytic-uremic syndrome with intravascular hemolysis in a context of severe hypertension. A kidney biopsy showed a thrombotic microangiopathy. This observation highlights an uncommon side effect of long-term interferon beta-1a therapy. Pathophysiological mechanisms leading to this complication might be explained by the antiangiogenic activity of interferon.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>thrombotic microangiopathy</kwd>
        <kwd>interferon beta</kwd>
        <kwd>hemolytic-uremic syndrome</kwd>
        <kwd>antiangiogenic activity</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Thrombotic microangiopathies (TMA) are microvascular occlusive disorders characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) represent the two most frequently encountered clinical presentations of TMA. Sometimes TTP and HUS can overlap, and the clinical distinction between these two entities may be difficult to discern. The typical form of HUS occurs most commonly in children about a week after an episode of bloody diarrhea caused by <italic>Escherichia coli</italic> O157:H7. But infections with other <italic>E. coli</italic> serotypes also cause HUS in children and adults. Less frequently, there is no preceding diarrheal illness, and this form of the disease is known as atypical HUS (aHUS), and can either be sporadic or, when more than one member of a family is affected, familial.<xref ref-type="bibr" rid="b1-dddt-7-723">1</xref> Atypical HUS designates a primary disease caused by a disorder in complement alternative pathway regulation.<xref ref-type="bibr" rid="b2-dddt-7-723">2</xref> In both cases, there is an acute kidney disease.</p>
      <p>Although TMA has multiple etiologies, adverse effects of drugs have been increasingly reported for several years as probable causes of TMA.<xref ref-type="bibr" rid="b3-dddt-7-723">3</xref> Drug-associated TMA can be an acute, immune-mediated disorder or the result of gradual, dose-dependent toxicity.<xref ref-type="bibr" rid="b4-dddt-7-723">4</xref> Interferon alpha (IFN&#x3B1;) has been implicated in the development of lesions of thrombotic microangiopathies in patients treated for chronic myeloid leukemia.<xref ref-type="bibr" rid="b5-dddt-7-723">5</xref> We speculate that interferon beta-1a (IFN&#x3B2;-1a) therapy may be involved in the development of TMA, and we propose a hypothesis for the mechanism by the antiangiogenic activity of interferon (IFN) to explain this.</p>
      <p>Here we report the case of a woman who has been treated for 5 years with IFN&#x3B2;-1a for multiple sclerosis (MS), and has developed renal failure with hypertension due to TMA with clinical presentation of HUS.</p>
    </sec>
    <sec>
      <title>Case report</title>
      <p>The 38-year-old Caucasian woman was diagnosed with MS in August 2006. Treatment was started 7 months later with IFN&#x3B2;-1a (Rebif&#xAE;, Merck Serono Europe Limited, London, UK) and before this, no treatment was initiated. The IFN&#x3B2; therapy was well tolerated for 5 years, with ibuprofen and acetaminophen also taken to treat flu-like symptoms. In recent years, she reported using oxcarbazepine therapy for neuralgia and a clonazepam therapy for cramps, but these drugs were taken over a short period of time.</p>
      <p>For several weeks before the first admittance in our hospital, she reported a history of asthenia, cramps, headaches, and anorexia with weight loss. Discovery of anemia motivated the hospital admission of the patient.</p>
      <p>At admission, the patient showed evidence of kidney insufficiency in the context of severe hypertension (180/130 mmHg). Laboratory investigations are summarized in <xref ref-type="table" rid="t1-dddt-7-723">Table 1</xref>.</p>
      <p>Viral, bacteriological, and immunological studies, including antinuclear antibodies, were all etiologically negative. The results of gene mutation analysis in Factor H, Factor I, membrane cofactor protein (MCP), complement C3 and Factor B were also negative.</p>
      <p>A kidney biopsy revealed both acute and chronic lesions of TMA. A few glomeruli presented with capillary-loop double contours, fibrin thrombi, and zones of mesangiolysis (<xref ref-type="fig" rid="f1-dddt-7-723">Figure 1</xref>). One arteriole showed marked mucoid intimal expansion with focal fibrinoid necrosis (<xref ref-type="fig" rid="f2-dddt-7-723">Figure 2</xref>). Chronic ischemic changes were predominant, with diffuse interstitial fibrosis, tubular atrophy, extensive ischemic changes in glomeruli, and severe fibrous intimal thickening of interlobular arteries (<xref ref-type="fig" rid="f3-dddt-7-723">Figure 3</xref>).</p>
      <p>During the 7 days of hospitalization, a symptomatic treatment with red blood cell transfusion resulted in the correction of anemia. Blood pressure control was initially achieved with intravenous nicardipine therapy and relayed with triple antihypertensive therapy (propranolol, amlodipine, and irbesartan). Consequently, IFN&#x3B2;-1a was discontinued. At the end of hospitalization, kidney failure persisted in this patient, consistent with the chronic lesion identified on kidney biopsy.</p>
      <p>One month after the first episode, the patient was readmitted following difficulties in controlling blood pressure (140/100 mmHg) and kidney function deterioration (<xref ref-type="table" rid="t1-dddt-7-723">Table 1</xref>). During the second admittance there was no biological argument in favor of a recurrence of TMA: no biological argument for mechanical hemolysis, and complement C3 and C4 levels were normal. The introduction of urapidil, an adrenergic alpha-1 receptor antagonist, was required for blood pressure control, in addition to the triple therapy already established. At the end of 7 days of hospitalization, the blood pressure control was achieved (110/80 mmHg).</p>
      <p>Nine months after the last hospitalization, the patient has chronic kidney disease with stabilization of creatinine 225 &#x3BC;mol/L and creatinine clearance at 22 mL/min (estimated using the modification of diet in renal disease [MDRD] formula). She is not receiving dialysis, and her hypertension is controlled with irbesartan, furosemide (switched to urapidil) and propranolol. The patient is currently neurologically stable, and she is not undergoing treatment for MS.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>IFNs are cytokines that mediate antiviral, antiproliferative, and immunomodulatory activities. IFN&#x3B2;-1a is prescribed for the treatment of relapsing forms of MS to slow down the development of physical disability and decrease the frequency of clinical exacerbations.</p>
      <p>IFN therapy is associated with adverse effects such as flu-like symptoms, asthenia, anorexia, and injection site reaction. Renal side effects are uncommon, but severe manifestations are reported, including acute renal failure related to acute tubular necrosis, or acute interstitial nephritis, hemolytic-uremic syndrome, focal segmental glomerulosclerosis, and minimal change disease.<xref ref-type="bibr" rid="b6-dddt-7-723">6</xref> These side effects are more often associated with IFN&#x3B1; therapy rather than IFN&#x3B2;. TMA caused by IFN&#x3B1; therapy has been reported for several years.<xref ref-type="bibr" rid="b7-dddt-7-723">7</xref></p>
      <p>The concept that the TMA presented by our patient was secondarily related to IFN&#x3B2; treatment is supported by several factors.</p>
      <p>Concerning the concomitant medications, the literature does not describe TMA induction by ibuprofen and acetaminophen, moreover, oxcarbazepine and clonazepam were taken several years before the first hospitalization and over a short period.</p>
      <p>The patient presented with an increased blood pressure (180/130 mmHg) before the first hospitalization, and severe or malignant hypertension may accompany TMA.<xref ref-type="bibr" rid="b8-dddt-7-723">8</xref> The pathological changes from kidney damage in malignant hypertension are sometimes similar to renal lesions in HUS/TTP, leading to difficulties in the differential diagnosis for other TMA etiologies.<xref ref-type="bibr" rid="b9-dddt-7-723">9</xref> Among the conditions linked to TMA, malignant hypertension is associated with a predominance of vascular rather than glomerular findings.<xref ref-type="bibr" rid="b10-dddt-7-723">10</xref> In our case, the patient had no medical history of hypertension, and the IFN&#x3B2; therapy is not known to be associated to the occurrence of hypertension. She also had no sign of malignant hypertension.</p>
      <p>The presence of antiphospholipid antibodies can be induced by IFN therapy: Piette et al suggested the role of antiphospholipid antibodies in hemolytic-uremic syndrome induced by IFN&#x3B1;.<xref ref-type="bibr" rid="b11-dddt-7-723">11</xref> The presence of antiphospholipid antibodies was found in patients who have been diagnosed with MS since they can be induced by IFN therapy.<xref ref-type="bibr" rid="b12-dddt-7-723">12</xref> In our case, autoimmune serologies were negative, including antiphospholipid antibodies.</p>
      <p>Genetic abnormalities in the complement cascade are associated in approximately 50% of patients with atypical HUS.<xref ref-type="bibr" rid="b13-dddt-7-723">13</xref> Six different mutations in genes coding for various components of the complement alternative pathway (Factor H, Factor I, Factor B, MCP, thrombomodulin, and C3 complement component) have been identified to date.<xref ref-type="bibr" rid="b14-dddt-7-723">14</xref>&#x2013;<xref ref-type="bibr" rid="b16-dddt-7-723">16</xref> In our case, there is no evidence in favor of gene abnormalities as the results of genetic analysis were negative.</p>
      <p>Activity of von Willebrand protease factor was not assessed in our case report. An ADAMTS 13 (A disintegrin and metalloproteinase with thrombospondin 1 motifs) deficiency could be due to autoantibodies against various epitopes of this protease during treatment with IFN&#x3B1;-2a.<xref ref-type="bibr" rid="b17-dddt-7-723">17</xref> This could explain the formation of occlusive platelet thrombi in microvessels, but no similar mechanism has been described with IFN&#x3B2;.</p>
      <p>Several hypotheses have been proposed to explain the mechanisms that can lead to TMA development with IFN therapy, but none can be considered in this case. The pathogenesis of TMA may involve inhibition of vascular endothelial cell growth factor (VEGF) in renal podocytes.<xref ref-type="bibr" rid="b4-dddt-7-723">4</xref> VEGF stimulates signal transduction pathways and transcriptional programs through activation of its receptor, VEGFR2.<xref ref-type="bibr" rid="b18-dddt-7-723">18</xref> These events are essential for de novo formation of blood vessels (ie, angiogenesis, a process that involves proliferation and migration of endothelial cells),<xref ref-type="bibr" rid="b14-dddt-7-723">14</xref> while this process is inhibited by cytokines of the type 1 IFN family (including IFN-&#x3B1;/&#x3B2;).<xref ref-type="bibr" rid="b19-dddt-7-723">19</xref> IFN-&#x3B1;/&#x3B2; exert their effects via binding to the type 1 IFN receptor and activation of Janus kinases and signal transducers, and activators of transcription.<xref ref-type="bibr" rid="b20-dddt-7-723">20</xref> The role of VEGF in renal physiology is not completely known,<xref ref-type="bibr" rid="b21-dddt-7-723">21</xref> but it has been involved in the pathophysiology of several renal diseases, and TMA is a lesion commonly reported with anti-VEGF drugs. Also IFN therapy could be considered as an etiological agent to TMA through this antiangiogenic activity.</p>
      <p>Both clinical presentations of TMA, TTP and HUS are listed in the Summary of Product Characteristics of IFN&#x3B2;-1a (Rebif&#xAE;), and were identified during the postmarketing surveillance.<xref ref-type="bibr" rid="b22-dddt-7-723">22</xref></p>
      <p>A literature review in the PubMed database was carried out, and to our knowledge, this is the sixth case of TMA induced by IFN&#x3B2;. A summary of TMA case reports induced by IFN&#x3B2; is presented in <xref ref-type="table" rid="t2-dddt-7-723">Table 2</xref>. In one case, the patient developed systematic lupus erythematosus, positive antiphospholipid antibodies, and acute renal failure due to thrombotic microangiopathy. The TMA may be associated with systematic lupus erythematosus or antiphospholipid syndrome, and it is difficult to speculate on the role of IFN therapy.<xref ref-type="bibr" rid="b23-dddt-7-723">23</xref> Moreover, there are few reported cases of systematic lupus erythematosus linked to IFN&#x3B2; therapy.<xref ref-type="bibr" rid="b24-dddt-7-723">24</xref></p>
      <p>For two other cases, the therapy duration was very short (44 days and 2 weeks),<xref ref-type="bibr" rid="b25-dddt-7-723">25</xref>,<xref ref-type="bibr" rid="b26-dddt-7-723">26</xref> while a hypothesis suggests that the cumulative effects of IFN may result in the development of renal lesions.<xref ref-type="bibr" rid="b27-dddt-7-723">27</xref> TMA occurred several months or years after starting the treatment with IFN-&#x3B1;,<xref ref-type="bibr" rid="b5-dddt-7-723">5</xref> whereas other nephropathies are usually diagnosed in the first weeks of treatment. The duration of IFN therapy may therefore be the cause of some cumulative endothelial toxicity, which corroborated with our patient, who has been receiving IFN&#x3B2;-1a for 5 years.</p>
      <p>A search in the French Pharmacovigilance Database using the terms &#x201C;thrombotic microangiopathy&#x201D;/&#x201C;thrombotic thrombocytopenic purpura&#x201D;/&#x201C;hemolytic-uremic syndrome&#x201D; combined with &#x201C;interferon beta-1a&#x201D; found ten other cases. The notifications with renal biopsy confirming the diagnosis of TMA only are presented in <xref ref-type="table" rid="t3-dddt-7-723">Table 3</xref>. For two cases, the investigations showed an ADAMTS 13 deficiency (with anti-ADAMTS 13 autoantibodies for one case), and for one case, the patient serum was positive for antiphospholipid antibodies. For all notifications, the delay of IFN therapy was consistent with the hypothesis of cumulative effects.</p>
      <p>In conclusion, our observations added to the other reported cases, support the hypothesis that IFN&#x3B2;-1a is a causative agent in the occurrence of TMA. A serious renal prognosis with chronic kidney disease was reported in most of these cases. Assessing kidney function and detecting the onset of hypertension is justified to identify renal toxicity as soon as possible during IFN&#x3B2; therapy.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Disclosure</bold>
        </p>
        <p>The authors report no conflicts of interest in this work.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="b1-dddt-7-723">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noris</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Atypical hemolytic-uremic syndrome</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>361</volume>
          <issue>17</issue>
          <fpage>1676</fpage>
          <lpage>1687</lpage>
          <pub-id pub-id-type="pmid">19846853</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-dddt-7-723">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warwicker</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Goodship</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Donne</surname>
              <given-names>RL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic studies into inherited and sporadic hemolytic uremic syndrome</article-title>
          <source>Kidney Int</source>
          <year>1998</year>
          <volume>53</volume>
          <issue>4</issue>
          <fpage>836</fpage>
          <lpage>844</lpage>
          <pub-id pub-id-type="pmid">9551389</pub-id>
        </element-citation>
      </ref>
      <ref id="b3-dddt-7-723">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Medina</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Sipols</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
          <article-title>Drug associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome</article-title>
          <source>Curr Opin Hematol</source>
          <year>2001</year>
          <volume>8</volume>
          <issue>5</issue>
          <fpage>286</fpage>
          <lpage>293</lpage>
          <pub-id pub-id-type="pmid">11604563</pub-id>
        </element-citation>
      </ref>
      <ref id="b4-dddt-7-723">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Terrell</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Vesely</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Kremer Hovinga</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer</article-title>
          <source>Presse Med</source>
          <year>2012</year>
          <volume>41</volume>
          <issue>3 Pt 2</issue>
          <fpage>e177</fpage>
          <lpage>e188</lpage>
          <pub-id pub-id-type="pmid">22244728</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-dddt-7-723">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zuber</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Droz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Oksenhendler</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Legendre</surname>
              <given-names>C</given-names>
            </name>
            <collab>Groupe D&#x2019;&#xE9;tude Des Nephrologues D&#x2019;ile-de-France (GENIF)</collab>
          </person-group>
          <article-title>Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature</article-title>
          <source>Medicine (Baltimore)</source>
          <year>2002</year>
          <volume>81</volume>
          <issue>4</issue>
          <fpage>321</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="pmid">12169887</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-dddt-7-723">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aravindan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Killingsworth</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suranyi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Minimal change disease with interferon-beta therapy for relapsing remitting multiple sclerosis</article-title>
          <source>NDT Plus</source>
          <year>2010</year>
          <volume>3</volume>
          <issue>2</issue>
          <fpage>132</fpage>
          <lpage>134</lpage>
        </element-citation>
      </ref>
      <ref id="b7-dddt-7-723">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harvey</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence?</article-title>
          <source>Am J Hematol</source>
          <year>1994</year>
          <volume>46</volume>
          <issue>2</issue>
          <fpage>152</fpage>
          <lpage>153</lpage>
          <pub-id pub-id-type="pmid">8172186</pub-id>
        </element-citation>
      </ref>
      <ref id="b8-dddt-7-723">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaughan</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Delanty</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Hypertensive emergencies</article-title>
          <source>Lancet</source>
          <year>2000</year>
          <volume>356</volume>
          <issue>9227</issue>
          <fpage>411</fpage>
          <lpage>417</lpage>
          <pub-id pub-id-type="pmid">10972386</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-dddt-7-723">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Renal thrombotic microangiopathies induced by severe hypertension</article-title>
          <source>Hypertens Res</source>
          <year>2008</year>
          <volume>31</volume>
          <issue>3</issue>
          <fpage>479</fpage>
          <lpage>483</lpage>
          <pub-id pub-id-type="pmid">18497467</pub-id>
        </element-citation>
      </ref>
      <ref id="b10-dddt-7-723">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Halevy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Radhakrishnan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Markowitz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Appel</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic microangiopathies</article-title>
          <source>Crit Care Clin</source>
          <year>2002</year>
          <volume>18</volume>
          <issue>2</issue>
          <fpage>309</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="pmid">12053836</pub-id>
        </element-citation>
      </ref>
      <ref id="b11-dddt-7-723">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piette</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Papo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Potential role for antiphospholipid antibodies in renal thrombotic microangiopathy induced by interferon-alpha</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>1995</year>
          <volume>10</volume>
          <issue>9</issue>
          <fpage>1781</fpage>
          <pub-id pub-id-type="pmid">8559510</pub-id>
        </element-citation>
      </ref>
      <ref id="b12-dddt-7-723">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>IJdo</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Conti-Kelly</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Greco</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?</article-title>
          <source>Lupus</source>
          <year>1999</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>109</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="pmid">10192504</pub-id>
        </element-citation>
      </ref>
      <ref id="b13-dddt-7-723">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malina</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Roumenina</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Seeman</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetics of hemolytic uremic syndromes</article-title>
          <source>Presse Med</source>
          <year>2012</year>
          <volume>41</volume>
          <issue>3 Pt 2</issue>
          <fpage>e105</fpage>
          <lpage>e114</lpage>
          <pub-id pub-id-type="pmid">22265161</pub-id>
        </element-citation>
      </ref>
      <ref id="b14-dddt-7-723">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warwicker</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Goodship</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Donne</surname>
              <given-names>RL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic studies into inherited and sporadic hemolytic uremic syndrome</article-title>
          <source>Kidney Int</source>
          <year>1998</year>
          <volume>53</volume>
          <issue>4</issue>
          <fpage>836</fpage>
          <lpage>844</lpage>
          <pub-id pub-id-type="pmid">9551389</pub-id>
        </element-citation>
      </ref>
      <ref id="b15-dddt-7-723">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Richards</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kemp</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Liszewski</surname>
              <given-names>MK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2003</year>
          <volume>100</volume>
          <issue>22</issue>
          <fpage>12966</fpage>
          <lpage>12971</lpage>
          <pub-id pub-id-type="pmid">14566051</pub-id>
        </element-citation>
      </ref>
      <ref id="b16-dddt-7-723">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fremeaux-Bacchi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Dragon-Durey</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Blouin</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome</article-title>
          <source>J Med Genet</source>
          <year>2004</year>
          <volume>41</volume>
          <issue>6</issue>
          <fpage>e84</fpage>
          <pub-id pub-id-type="pmid">15173250</pub-id>
        </element-citation>
      </ref>
      <ref id="b17-dddt-7-723">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moake</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic microangiopathies</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>347</volume>
          <issue>8</issue>
          <fpage>589</fpage>
          <lpage>600</lpage>
          <pub-id pub-id-type="pmid">12192020</pub-id>
        </element-citation>
      </ref>
      <ref id="b18-dddt-7-723">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrara</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Vascular endothelial growth factor: basic science and clinical progress</article-title>
          <source>Endocr Rev</source>
          <year>2004</year>
          <volume>25</volume>
          <issue>4</issue>
          <fpage>581</fpage>
          <lpage>611</lpage>
          <pub-id pub-id-type="pmid">15294883</pub-id>
        </element-citation>
      </ref>
      <ref id="b19-dddt-7-723">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sidky</surname>
              <given-names>YA</given-names>
            </name>
            <name>
              <surname>Borden</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses</article-title>
          <source>Cancer Res</source>
          <year>1987</year>
          <volume>47</volume>
          <issue>19</issue>
          <fpage>5155</fpage>
          <lpage>5161</lpage>
          <pub-id pub-id-type="pmid">2441862</pub-id>
        </element-citation>
      </ref>
      <ref id="b20-dddt-7-723">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aaronson</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Horvath</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>A road map for those who don&#x2019;t know JAK-STAT</article-title>
          <source>Science</source>
          <year>2002</year>
          <volume>296</volume>
          <issue>5573</issue>
          <fpage>1653</fpage>
          <lpage>1655</lpage>
          <pub-id pub-id-type="pmid">12040185</pub-id>
        </element-citation>
      </ref>
      <ref id="b21-dddt-7-723">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schrijvers</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Flyvbjerg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>De Vriese</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>The role of vascular endothelial growth factor (VEGF) in renal pathophysiology</article-title>
          <source>Kidney Int</source>
          <year>2004</year>
          <volume>65</volume>
          <issue>6</issue>
          <fpage>2003</fpage>
          <lpage>2017</lpage>
          <pub-id pub-id-type="pmid">15149314</pub-id>
        </element-citation>
      </ref>
      <ref id="b22-dddt-7-723">
        <label>22</label>
        <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ema.europa.eu [homepage on the Internet]</collab></person-group><source>Summary of product characteristics of Rebif&#xAE;</source><comment>[updated 2013 April 18] Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/ema/">http://www.ema.europa.eu/ema/</ext-link></comment>Accessed <date-in-citation>June 26, 2013</date-in-citation></mixed-citation>
      </ref>
      <ref id="b23-dddt-7-723">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hansen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>New</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Reeve</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Donne</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Acute renal failure, systemic lupus erythematosus and thrombotic microangiopathy following treatment with beta-interferon for multiple sclerosis: case report and review of the literature</article-title>
          <source>NDT Plus</source>
          <year>2009</year>
          <volume>2</volume>
          <issue>6</issue>
          <fpage>466</fpage>
          <lpage>468</lpage>
        </element-citation>
      </ref>
      <ref id="b24-dddt-7-723">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crispin</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Diaz-Jouanen</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis</article-title>
          <source>Lupus</source>
          <year>2005</year>
          <volume>14</volume>
          <issue>6</issue>
          <fpage>495</fpage>
          <lpage>496</lpage>
          <pub-id pub-id-type="pmid">16038117</pub-id>
        </element-citation>
      </ref>
      <ref id="b25-dddt-7-723">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ubara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hara</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takedatu</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C</article-title>
          <source>Nephron</source>
          <year>1998</year>
          <volume>80</volume>
          <issue>1</issue>
          <fpage>107</fpage>
          <lpage>108</lpage>
          <pub-id pub-id-type="pmid">9730725</pub-id>
        </element-citation>
      </ref>
      <ref id="b26-dddt-7-723">
        <label>26</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Herrera</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Balizet</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Harberts</surname>
              <given-names>SW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Occurrence of a TTP-like syndrome in two women receiving beta interferon therapy for relapsing multiple sclerosis [American Academy of Neurology 51st annual meeting. Toronto, Ontario, Canada. April 17&#x2013;24, 1999. Abstracts]</article-title>
          <source>Neurology</source>
          <year>1999</year>
          <volume>52</volume>
          <issue>6 Suppl. 2</issue>
          <fpage>A135</fpage>
        </element-citation>
      </ref>
      <ref id="b27-dddt-7-723">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Broughton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cosyns</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Jadoul</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic microangiopathy induced by long-term interferon-&#x3B2; therapy for multiple sclerosis: a case report</article-title>
          <source>Clin Nephrol</source>
          <year>2011</year>
          <volume>76</volume>
          <issue>5</issue>
          <fpage>396</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="pmid">22000560</pub-id>
        </element-citation>
      </ref>
      <ref id="b28-dddt-7-723">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olea</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>D&#xED;az-Mancebo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Picazo</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Mart&#xED;nez-Ara</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Robles</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Selgas</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic microangiopathy associated with use of interferon-beta</article-title>
          <source>Int J Nephrol Renovasc Dis</source>
          <year>2012</year>
          <volume>5</volume>
          <fpage>97</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="pmid">22815645</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-dddt-7-723" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Acute glomerular lesion.</p>
        <p><bold>Notes:</bold> There is global thickening of glomerular capillary walls caused by subendothelial expansion associated with focal mesangiolysis and a few capillary thrombosis (HES &#xD7;400 magnification).</p>
        <p><bold>Abbreviation:</bold> HES, hematoxylin, eosin, saffron.</p>
      </caption>
      <graphic xlink:href="dddt-7-723Fig1"/>
    </fig>
    <fig id="f2-dddt-7-723" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Acute arteriolar lesion.</p>
        <p><bold>Notes:</bold> Mucoid intimal thickening with focal fibrinoid necrosis is responsible for occlusion of the lumen (HES &#xD7;400 magnification).</p>
        <p><bold>Abbreviation:</bold> HES, hematoxylin, eosin, saffron.</p>
      </caption>
      <graphic xlink:href="dddt-7-723Fig2"/>
    </fig>
    <fig id="f3-dddt-7-723" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Severe chronic ischemic changes.</p>
        <p><bold>Notes:</bold> There is diffuse interstitial fibrosis with focal tubular atrophy. The three glomerular (on the left) show severe wrinkling of the basement membranes with sclerotic changes. The interlobular artery shows marked intimal fibrous thickening with resultant severe narrowing of the lumen (trichrome &#xD7;200 magnification).</p>
      </caption>
      <graphic xlink:href="dddt-7-723Fig3"/>
    </fig>
    <table-wrap id="t1-dddt-7-723" position="float">
      <label>Table 1</label>
      <caption>
        <p>Laboratory test results during hospital admissions</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="2" align="left" valign="top" colspan="1">Test item</th>
            <th colspan="2" align="left" valign="top" rowspan="1">First hospitalization
<hr/></th>
            <th colspan="2" align="left" valign="top" rowspan="1">Second hospitalization
<hr/></th>
          </tr>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">At admission</th>
            <th align="left" valign="top" rowspan="1" colspan="1">At discharge (7th day)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">At admission</th>
            <th align="left" valign="top" rowspan="1" colspan="1">At discharge (7th day)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Serum creatinine (&#x3BC;mol/L)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">211</td>
            <td align="left" valign="top" rowspan="1" colspan="1">257</td>
            <td align="left" valign="top" rowspan="1" colspan="1">465</td>
            <td align="left" valign="top" rowspan="1" colspan="1">501</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Serum urea (mmol/L)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">13</td>
            <td align="left" valign="top" rowspan="1" colspan="1">13.9</td>
            <td align="left" valign="top" rowspan="1" colspan="1">13.9</td>
            <td align="left" valign="top" rowspan="1" colspan="1">25.6</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Protein total (g/L)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">59</td>
            <td align="left" valign="top" rowspan="1" colspan="1">54</td>
            <td align="left" valign="top" rowspan="1" colspan="1">64</td>
            <td align="left" valign="top" rowspan="1" colspan="1">62</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Lactate dehydrogenase (IU/L)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">923</td>
            <td align="left" valign="top" rowspan="1" colspan="1">287</td>
            <td align="left" valign="top" rowspan="1" colspan="1">285</td>
            <td align="left" valign="top" rowspan="1" colspan="1">194</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Creatinine clearance (mL/min estimated with MDRD formula)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">18</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">8</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Hemoglobin (g/L)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">80.3</td>
            <td align="left" valign="top" rowspan="1" colspan="1">112</td>
            <td align="left" valign="top" rowspan="1" colspan="1">96</td>
            <td align="left" valign="top" rowspan="1" colspan="1">103</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Haptoglobin (g/L)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0.35</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">1.14</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Platelets (&#xD7;10<sup>9</sup>/L)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">167</td>
            <td align="left" valign="top" rowspan="1" colspan="1">294</td>
            <td align="left" valign="top" rowspan="1" colspan="1">330</td>
            <td align="left" valign="top" rowspan="1" colspan="1">353</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Schistocytes</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Positive</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Negative</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Negative</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Negative</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">C3 complement (g/L)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1.18</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1.16</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">C4 complement (g/L)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0.29</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0.28</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Autoantibodies (<xref ref-type="table-fn" rid="tfn1-dddt-7-723">*</xref>)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Negative</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>
            <bold>Notes:</bold>
          </p>
        </fn>
        <fn id="tfn1-dddt-7-723">
          <label>*</label>
          <p>Autoantibodies included anti-nuclear antibodies, anti-neutrophil cytoplasmic antibodies, anti-GBM antibodies and anti-phospholipids. - indicates results not available.</p>
        </fn>
        <fn id="tfn2-dddt-7-723">
          <p><bold>Abbreviations:</bold> MDRD, modification of diet in renal disease; GBM, glomerular basement membrane.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t2-dddt-7-723" position="float">
      <label>Table 2</label>
      <caption>
        <p>Summary of thrombotic microangiopathy case reports induced by interferon beta (IFN&#x3B2;) therapy from literature review</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">Authors</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Year</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Age of patient</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Indication of IFN&#x3B2;-1a therapy</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Duration of therapy</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Clinical</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Laboratory investigations</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Treatment</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Outcome</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Ubara et al<xref ref-type="bibr" rid="b25-dddt-7-723">25</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">1998</td>
            <td align="left" valign="top" rowspan="1" colspan="1">66</td>
            <td align="left" valign="top" rowspan="1" colspan="1">HCV</td>
            <td align="left" valign="top" rowspan="1" colspan="1">44 days</td>
            <td align="left" valign="top" rowspan="1" colspan="1">HUS</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Remission</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Herrera et al<xref ref-type="bibr" rid="b26-dddt-7-723">26</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">1999</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2 weeks</td>
            <td align="left" valign="top" rowspan="1" colspan="1">TTP</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + plasmapheresis</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney disease</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Hansen et al<xref ref-type="bibr" rid="b23-dddt-7-723">23</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">2009</td>
            <td align="left" valign="top" rowspan="1" colspan="1">41</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Several years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Renal failure + SLE + APS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Antinuclear-antibodies and antiphospholipid positive</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + plasmapheresis + steroids + mycophenolate mofetil</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney disease</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Broughton et al<xref ref-type="bibr" rid="b27-dddt-7-723">27</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">2011</td>
            <td align="left" valign="top" rowspan="1" colspan="1">53</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">8 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Renal failure + mild hypertension</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + lisinopril</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney disease</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Olea et al<xref ref-type="bibr" rid="b28-dddt-7-723">28</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">2012</td>
            <td align="left" valign="top" rowspan="1" colspan="1">37</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">5 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Renal failure + severe hypertension</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + steroids + enalapril + irbesartan</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Remission</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn3-dddt-7-723">
          <p><bold>Abbreviations:</bold> APS, anti-phospholipid syndrome; SLE, systemic lupus erythematosus; HUS, hemolytic-uremic syndrome; MS, multiple sclerosis; TTP, thrombotic thrombocytopenic purpura; HCV, hepatitis C virus; N/A, not available.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t3-dddt-7-723" position="float">
      <label>Table 3</label>
      <caption>
        <p>Summary of thrombotic microangiopathy notifications induced by interferon beta-1a (IFN&#x3B2;) from French Pharmacovigilance Database</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">Year</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Age</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Duration of treatment</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Disease</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Clinical</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Treatment</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Laboratory investigations</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Outcome</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">2006</td>
            <td align="left" valign="top" rowspan="1" colspan="1">47</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1 year</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Proteinuria</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2;</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Remission</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">2007</td>
            <td align="left" valign="top" rowspan="1" colspan="1">58</td>
            <td align="left" valign="top" rowspan="1" colspan="1">5 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">HUS + hypertension</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + plasmapheresis + steroids</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney disease</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">2008</td>
            <td align="left" valign="top" rowspan="1" colspan="1">55</td>
            <td align="left" valign="top" rowspan="1" colspan="1">6 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">TTP</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + plasmapheresis + steroids + rituximab</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IgG anti-ADAMTS 13 positive</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Remission</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">2009</td>
            <td align="left" valign="top" rowspan="1" colspan="1">66</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1 year</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">HUS + hypertension</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + urapidil</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Remission</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">2009</td>
            <td align="left" valign="top" rowspan="1" colspan="1">65</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1 year</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Nephrotic syndrome</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">2010</td>
            <td align="left" valign="top" rowspan="1" colspan="1">38</td>
            <td align="left" valign="top" rowspan="1" colspan="1">10 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">TTP</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + plasmapheresis + steroids</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">2011</td>
            <td align="left" valign="top" rowspan="1" colspan="1">44</td>
            <td align="left" valign="top" rowspan="1" colspan="1">3 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Renal failure + hypertension</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + plasmapheresis</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Antinuclear-antibodies positive</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney disease</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">2012</td>
            <td align="left" valign="top" rowspan="1" colspan="1">52</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&gt;3 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">HUS + hypertension</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Discontinuation of IFN&#x3B2; + plasmapheresis + nebivolol</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Decreased activity of ADAMTS 13</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney disease</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn4-dddt-7-723">
          <p><bold>Abbreviations:</bold> ADAMTS, A disintegrin and metalloproteinase with thrombospondin 1 motifs; Ig, immunoglobulin; NA, not available; HUS, hemolytic-uremic syndrome; MS, multiple sclerosis; TTP, thrombotic thrombocytopenic purpura.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
